FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379345974> ?p ?o ?g. }

• W4379345974 endingPage "7006" @default.
• W4379345974 startingPage "7006" @default.
• W4379345974 abstract "7006 Background: Older adult patients (pts) with Philadelphia-chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) have poor survival with chemotherapy. The α-CD22 Ab-drug conjugate inotuzumab ozogamicin (InO) and α-CD19/CD3 T-cell engager blinatumomab (blina) were each superior to chemotherapy in Phase III studies in relapsed/refractory B-ALL. Because InO induces high CR rates and blina can induce durable remissions in low burden disease, we conducted a Phase II trial of induction InO then blina for older adults with newly-diagnosed (ND), Ph-, B-ALL. Methods: Eligible were pts ≥60 years old with ND, Ph-, CD22+ (≥20% of blasts) B-ALL without plan for allogeneic HCT (alloHCT). Pts with CNS leukemia or liver disease were excluded. Induction IA was InO 0.8 mg/m 2 day (d) 1, 0.5 mg/m 2 d8, d15 IV on a 21d cycle. Pts with adequate cytoreduction (marrow blasts by ≥50% or cellularity ≤20%) after IA went to IB if in CR/CRi (InO 0.5 mg/m 2 d1, d8, d15 IV; 28d cycle) or IC if no CR/CRi (InO 0.8 mg/m 2 d1, d8, d15 IV; 28d cycle). Those without cytoreduction to IA started course II blina. Pts without events in IA/B/C received course II blina CIV (9 mcg/d x 7d then 28 mcg/d x 21d; 14d break; 28 mcg/d x28d). Pts with CR/CRi to InO received 2 more 28d cycles of blina, others received 3 more. CNS prophylaxis was methotrexate 15 mg intrathecal x 8. The primary endpoint was 1-yr event-free survival (EFS) with a lower limit of a 90% CI for 1-yr EFS >10% defined as success. EFS was the time from therapy start to failure to achieve CR/CRh/CRi by end Course II, progression, relapse, or death, whichever occurred first. Results: Thirty-three eligible pts were treated (1 ineligible, 2 nd malignancy). The median age was 71 years (range 60-84). Median WBC count was 3,200/mcl (range 6-38,000). Median CD22 expression was 92% (range 21-100%). Eight pts had therapy-related ALL. The cumulative CR rates through Course IA/B/C and Course II were 85% and 97%, respectively (Table). With median follow up of 22 mo, the 1-yr EFS was 75% (95% CI 61-92%). The 2-sided 90% CI was 63-89% for 1-yr EFS with lower bound above 10% indicating regimen success. Twelve pts had events: 9 relapses, 2 deaths in remission (1 after alloHCT), and 1 death without remission from respiratory failure with sinusoidal occlusion syndrome of liver. The 1-yr OS was 84% (95% CI 72-98%). Nine pts have died, 6 after relapse. Conclusions: InO induction then blina consolidation is highly active for ND, Ph-, CD22+ B-ALL. The regimen is an option for older adults and a comparator regimen for future studies. Support: U10CA180821, U10CA180882, U10CA180820 https://acknowledgments.alliancefound.org . Clinical trial information: NCT03739814 . [Table: see text]" @default.
• W4379345974 created "2023-06-05" @default.
• W4379345974 creator A5001278657 @default.
• W4379345974 creator A5003966906 @default.
• W4379345974 creator A5005939966 @default.
• W4379345974 creator A5007090031 @default.
• W4379345974 creator A5007647176 @default.
• W4379345974 creator A5011144900 @default.
• W4379345974 creator A5023287139 @default.
• W4379345974 creator A5023917898 @default.
• W4379345974 creator A5028241860 @default.
• W4379345974 creator A5031429271 @default.
• W4379345974 creator A5031554507 @default.
• W4379345974 creator A5050556099 @default.
• W4379345974 creator A5066185867 @default.
• W4379345974 creator A5071023119 @default.
• W4379345974 creator A5071796883 @default.
• W4379345974 creator A5085360755 @default.
• W4379345974 creator A5085699915 @default.
• W4379345974 date "2023-06-01" @default.
• W4379345974 modified "2023-09-25" @default.
• W4379345974 title "Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703." @default.
• W4379345974 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7006" @default.
• W4379345974 hasPublicationYear "2023" @default.
• W4379345974 type Work @default.
• W4379345974 citedByCount "1" @default.
• W4379345974 countsByYear W43793459742023 @default.
• W4379345974 crossrefType "journal-article" @default.
• W4379345974 hasAuthorship W4379345974A5001278657 @default.
• W4379345974 hasAuthorship W4379345974A5003966906 @default.
• W4379345974 hasAuthorship W4379345974A5005939966 @default.
• W4379345974 hasAuthorship W4379345974A5007090031 @default.
• W4379345974 hasAuthorship W4379345974A5007647176 @default.
• W4379345974 hasAuthorship W4379345974A5011144900 @default.
• W4379345974 hasAuthorship W4379345974A5023287139 @default.
• W4379345974 hasAuthorship W4379345974A5023917898 @default.
• W4379345974 hasAuthorship W4379345974A5028241860 @default.
• W4379345974 hasAuthorship W4379345974A5031429271 @default.
• W4379345974 hasAuthorship W4379345974A5031554507 @default.
• W4379345974 hasAuthorship W4379345974A5050556099 @default.
• W4379345974 hasAuthorship W4379345974A5066185867 @default.
• W4379345974 hasAuthorship W4379345974A5071023119 @default.
• W4379345974 hasAuthorship W4379345974A5071796883 @default.
• W4379345974 hasAuthorship W4379345974A5085360755 @default.
• W4379345974 hasAuthorship W4379345974A5085699915 @default.
• W4379345974 hasConcept C121332964 @default.
• W4379345974 hasConcept C126322002 @default.
• W4379345974 hasConcept C142424586 @default.
• W4379345974 hasConcept C2776694085 @default.
• W4379345974 hasConcept C2778020697 @default.
• W4379345974 hasConcept C2778245361 @default.
• W4379345974 hasConcept C2778461978 @default.
• W4379345974 hasConcept C2778729363 @default.
• W4379345974 hasConcept C2781107101 @default.
• W4379345974 hasConcept C2909962599 @default.
• W4379345974 hasConcept C71924100 @default.
• W4379345974 hasConcept C87355193 @default.
• W4379345974 hasConcept C90924648 @default.
• W4379345974 hasConceptScore W4379345974C121332964 @default.
• W4379345974 hasConceptScore W4379345974C126322002 @default.
• W4379345974 hasConceptScore W4379345974C142424586 @default.
• W4379345974 hasConceptScore W4379345974C2776694085 @default.
• W4379345974 hasConceptScore W4379345974C2778020697 @default.
• W4379345974 hasConceptScore W4379345974C2778245361 @default.
• W4379345974 hasConceptScore W4379345974C2778461978 @default.
• W4379345974 hasConceptScore W4379345974C2778729363 @default.
• W4379345974 hasConceptScore W4379345974C2781107101 @default.
• W4379345974 hasConceptScore W4379345974C2909962599 @default.
• W4379345974 hasConceptScore W4379345974C71924100 @default.
• W4379345974 hasConceptScore W4379345974C87355193 @default.
• W4379345974 hasConceptScore W4379345974C90924648 @default.
• W4379345974 hasFunder F4320332161 @default.
• W4379345974 hasIssue "16_suppl" @default.
• W4379345974 hasLocation W43793459741 @default.
• W4379345974 hasOpenAccess W4379345974 @default.
• W4379345974 hasPrimaryLocation W43793459741 @default.
• W4379345974 hasRelatedWork W2076411732 @default.
• W4379345974 hasRelatedWork W2095399864 @default.
• W4379345974 hasRelatedWork W2353191456 @default.
• W4379345974 hasRelatedWork W2357391729 @default.
• W4379345974 hasRelatedWork W2358739720 @default.
• W4379345974 hasRelatedWork W2391514770 @default.
• W4379345974 hasRelatedWork W2396499999 @default.
• W4379345974 hasRelatedWork W2914292410 @default.
• W4379345974 hasRelatedWork W3216657957 @default.
• W4379345974 hasRelatedWork W2531692626 @default.
• W4379345974 hasVolume "41" @default.
• W4379345974 isParatext "false" @default.
• W4379345974 isRetracted "false" @default.
• W4379345974 workType "article" @default.